COPLEY GRAND JURY SUBPOENA RELATES TO BROMPHERIL OTC
This article was originally published in The Tan Sheet
Executive Summary
COPLEY GRAND JURY SUBPOENA RELATES TO BROMPHERIL OTC antihistamine/decongestant combination product, the company disclosed on Sept. 14. The subpoena was handed down by the U.S. Attorney's Office in Boston on Aug. 23. In a Sept. 14 press release, Copley announced a voluntary recall of the extended- release brompheniramine/pseudoephedrine product due to concerns over manufacturing procedures. The Copley brand was the first equivalent to Schering's Drixoral extended-release product to be approved by FDA in January 1987.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning